. Author manuscript; available in PMC: 2013 Dec 2.

Published in final edited form as: Pharmacotherapy. 2011 May;31(5):10.1592/phco.31.5.449. doi: 10.1592/phco.31.5.449

Table 1.

Demographics, FEV₁, and Methacholine PC₂₀ During the Screening Visit for the 10 Study Patients

Patient No.	Sex/Age (yrs)	FEV₁, L (% predicted)	PC₂₀ (mg/ml)	Previous Therapy
3	M/29	4.07 (89)	0.61	Fluticasone-salmeterol, albuterol p.r.n.
7	F/26	2.40 (82)	0.62	Albuterol p.r.n.
12	F/52	1.85 (75)	0.42	Fluticasone, albuterol p.r.n.
13	M/25	3.17 (78)	4.70	Fluticasone-salmeterol, albuterol p.r.n.
20	F/29	2.79 (90)	0.61	Albuterol p.r.n.
21	F/54	1.91 (78)	1.38	Fluticasone-salmeterol, albuterol p.r.n.
29	F/49	1.89 (69)	0.34	Fluticasone-salmeterol, albuterol p.r.n.
30	M/25	3.35 (84)	2.27	Budesonide, albuterol p.r.n.
31	F/58	1.71 (78)	4.70	Fluticasone, albuterol p.r.n.
36	M/21	3.08 (72)	1.24	Albuterol p.r.n.
Mean ± SD	36.8 ± 14.5	2.6 ± 0.8 (79.5 ± 6.8)
Geometric mean			1.1 (95% CI 0.56–2.2)

FEV₁ = forced expiratory volume in 1 second; PC₂₀ = provocational concentration of methacholine required to decrease FEV₁ by 20%; CI = confidence interval.